Sort By

IL7 Recombinant Human Protein (Gibco™)

Recombinant Human Interleukin 7 (IL7) is a bioactive protein intended for use in cell culture applications. IL7 stimulates the proliferation of pre-B and pro-B cells. IL7 also supports the maturation of megakaryocytes.

High purity—no interference from other proteins or contaminants
High biological activity—more results with less protein
Proven compatibility—Gibco® proteins bioassayed with Gibco® media

High Purity Recombinant Bioactive Protein
Recombinant Human Interleukin 7 is one of our more than 250 available Gibco® recombinant proteins. To help ensure Gibco® growth factors are of the highest quality, each protein is analyzed for purity along with structural homogeneity to ensure a biologically active protein.

High Biological Activity
In-house activity testing of Gibco® Recombinant Proteins includes cell proliferation, cytotoxicity, chemotaxis, calcium flux, secondary cytokine up-regulation, induction of surface antigen expression, antiviral, and protease assays. Recombinant Human Interleukin 7 (IL7) specific activity is determined by the dose dependent proliferation of human PBMCs.

Proven Compatibility
Gibco® proteins are bioassayed with Gibco® media. Since 1962, Gibco® has been the consistent provider of high quality media, reagents, and sera for reliable cell culture.

See our selection of recombinant Gibco® growth factors.

For Research Use Only. Not intended for animal or human diagnostic or therapeutic use.

IL7 Recombinant Mouse Protein (Gibco™)

Recombinant IL7 is a bioactive protein intended for use in cell culture applications. IL7 stimulates the proliferation of pre-B and pro-B cells. IL7 also supports the maturation of megakaryocytes.

IL7 (Interleukin 7) CTS™ Recombinant Human Protein (Gibco™)

Recombinant IL7 is a bioactive protein intended for use in cell culture applications. IL7 stimulates the proliferation of pre-B and pro-B cells. IL7 also supports the maturation of megakaryocytes. ED50 range = 0.2 to 1 ng⁄mL (Specific Activity: 5.0 x 10^6 to 1.0 x 10^6 units⁄mg), determined by the dose dependent proliferation of human PBMCs. Optimal concentration for individual application should be determined by a dose response assay.